Lipocine Inc. (NASDAQ:LPCN) Short Interest Update

Lipocine Inc. (NASDAQ:LPCN) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 77,700 shares, a growth of 108.9% from the January 15th total of 37,200 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 33,200 shares, the short-interest ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Lipocine in a report on Monday. They set a “hold” rating on the stock.

Lipocine Trading Up 1.8 %

Shares of NASDAQ:LPCN traded up $0.07 during midday trading on Thursday, reaching $3.60. The company had a trading volume of 9,051 shares, compared to its average volume of 34,006. The stock has a market cap of $19.23 million, a P/E ratio of -4.73 and a beta of 1.23. The company’s 50 day moving average price is $4.66 and its 200 day moving average price is $4.67. Lipocine has a 52-week low of $3.20 and a 52-week high of $11.79.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC increased its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.